221 related articles for article (PubMed ID: 25513712)
1. Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase.
Fako VE; Wu X; Pflug B; Liu JY; Zhang JT
J Med Chem; 2015 Jan; 58(2):778-84. PubMed ID: 25513712
[TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitors suppress DNA damage repair and sensitize treatment resistance in breast cancer by targeting fatty acid synthase.
Wang CJ; Li D; Danielson JA; Zhang EH; Dong Z; Miller KD; Li L; Zhang JT; Liu JY
Cancer Lett; 2021 Jul; 509():1-12. PubMed ID: 33813001
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of emodin on fatty acid synthase, colon cancer proliferation and apoptosis.
Lee KH; Lee MS; Cha EY; Sul JY; Lee JS; Kim JS; Park JB; Kim JY
Mol Med Rep; 2017 Apr; 15(4):2163-2173. PubMed ID: 28260110
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Activity of the Lansoprazole Metabolite 5-Hydroxy Lansoprazole Sulfide in Triple-Negative Breast Cancer by Inhibiting the Enoyl Reductase of Fatty Acid Synthase.
Beebe J; Josephraj S; Wang CJ; Danielson J; Cui Q; Huang C; Barlow L; Zhang RH; Zhang T; Nakshatri H; Dong Z; Li X; Liu JY; Zhang JT
J Med Chem; 2022 Oct; 65(20):13681-13691. PubMed ID: 36257066
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?
Lupu R; Menendez JA
Curr Pharm Biotechnol; 2006 Dec; 7(6):483-93. PubMed ID: 17168665
[TBL] [Abstract][Full Text] [Related]
6. An Inhibitor of Fatty Acid Synthase Thioesterase Domain with Improved Cytotoxicity against Breast Cancer Cells and Stability in Plasma.
Lupien LE; Dunkley EM; Maloy MJ; Lehner IB; Foisey MG; Ouellette ME; Lewis LD; Pooler DB; Kinlaw WB; Baures PW
J Pharmacol Exp Ther; 2019 Oct; 371(1):171-185. PubMed ID: 31300609
[TBL] [Abstract][Full Text] [Related]
7. Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer.
Bauerschlag DO; Maass N; Leonhardt P; Verburg FA; Pecks U; Zeppernick F; Morgenroth A; Mottaghy FM; Tolba R; Meinhold-Heerlein I; Bräutigam K
J Transl Med; 2015 May; 13():146. PubMed ID: 25947066
[TBL] [Abstract][Full Text] [Related]
8. Fatty acid synthase inhibitors: new directions for oncology.
Kridel SJ; Lowther WT; Pemble CW
Expert Opin Investig Drugs; 2007 Nov; 16(11):1817-29. PubMed ID: 17970640
[TBL] [Abstract][Full Text] [Related]
9. Review on target domains and natural compound-based inhibitors of fatty acid synthase for anticancer drug discovery.
Pulla LSS; Begum Ahil S
Chem Biol Drug Des; 2021 Nov; 98(5):869-884. PubMed ID: 34459114
[TBL] [Abstract][Full Text] [Related]
10. [Fatty acid synthase: a new anti-tumor target].
Puig T; Porta R; Colomer R
Med Clin (Barc); 2009 Mar; 132(9):359-63. PubMed ID: 19268984
[TBL] [Abstract][Full Text] [Related]
11. Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines.
Hill TK; Davis AL; Wheeler FB; Kelkar SS; Freund EC; Lowther WT; Kridel SJ; Mohs AM
Mol Pharm; 2016 Mar; 13(3):720-8. PubMed ID: 26824142
[TBL] [Abstract][Full Text] [Related]
12. A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction.
Liu H; Liu Y; Zhang JT
Mol Cancer Ther; 2008 Feb; 7(2):263-70. PubMed ID: 18281512
[TBL] [Abstract][Full Text] [Related]
13. (-)-Epigallocatechin 3-Gallate Synthetic Analogues Inhibit Fatty Acid Synthase and Show Anticancer Activity in Triple Negative Breast Cancer.
Crous-Masó J; Palomeras S; Relat J; Camó C; Martínez-Garza Ú; Planas M; Feliu L; Puig T
Molecules; 2018 May; 23(5):. PubMed ID: 29751678
[TBL] [Abstract][Full Text] [Related]
14. In silico screening for identification of fatty acid synthase inhibitors and evaluation of their antiproliferative activity using human cancer cell lines.
Nisthul A A; Retnakumari AP; A S; Anto RJ; Sadasivan C
J Recept Signal Transduct Res; 2018 Aug; 38(4):335-341. PubMed ID: 30256698
[TBL] [Abstract][Full Text] [Related]
15. Diacylglycerol Metabolism and Signaling Is a Driving Force Underlying FASN Inhibitor Sensitivity in Cancer Cells.
Benjamin DI; Li DS; Lowe W; Heuer T; Kemble G; Nomura DK
ACS Chem Biol; 2015 Jul; 10(7):1616-23. PubMed ID: 25871544
[TBL] [Abstract][Full Text] [Related]
16. Fatty acid synthase inhibitors induce apoptosis in non-tumorigenic melan-a cells associated with inhibition of mitochondrial respiration.
Rossato FA; Zecchin KG; La Guardia PG; Ortega RM; Alberici LC; Costa RA; Catharino RR; Graner E; Castilho RF; Vercesi AE
PLoS One; 2014; 9(6):e101060. PubMed ID: 24964211
[TBL] [Abstract][Full Text] [Related]
17. Pyridine derivatives as anticancer lead compounds with Fatty Acid Synthase as the target: An in silico-guided in vitro study.
Amrutha NA; Archana PR; Mohan SG; Anto RJ; Sadasivan C
J Cell Biochem; 2019 Oct; 120(10):16643-16657. PubMed ID: 31095793
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in the Development of Fatty Acid Synthase Inhibitors as Anticancer Agents.
Singh S; Karthikeyan C; Moorthy NSHN
Mini Rev Med Chem; 2020; 20(18):1820-1837. PubMed ID: 32781957
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the thioesterase activity of human fatty acid synthase by 1,4- and 9,10-diones.
Odens H; Lowther T; Kridel S; Watts L; Filipponi L; Schmitt J
Chem Pharm Bull (Tokyo); 2014; 62(9):933-6. PubMed ID: 25177021
[TBL] [Abstract][Full Text] [Related]
20. Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators?
Lupu R; Menendez JA
Endocrinology; 2006 Sep; 147(9):4056-66. PubMed ID: 16809439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
